ALKERMES | ALKS - Le Coût Des Ventes





Le Coût Des Ventes Changement Date
AbbVie USD 4.22B 329M 2026-03
Acadia Pharmaceuticals USD 26.22M 4.58M 2025-12
ALKERMES USD 46.21M 5.38M 2025-12
Amgen USD 1.6B 187M 2026-03
Biogen USD 797.5M 302M 2026-03
BioMarin Pharmaceutical USD 199.48M 37.93M 2026-03
Bristol-Myers Squibb USD 3.86B 1.07B 2026-03
Coherus Biosciences USD 4.04M 324K 2025-12
Eli Lilly USD 3.58B 205M 2026-03
Gilead Sciences USD 1.62B 50M 2025-12
Heron Therapeutics USD 11.12M 795K 2025-12
Ionis Pharmaceuticals USD 3M 5M 2026-03
J&J USD 8.07B 103M 2026-03
Merck USD 2.94B 380M 2026-03
Minerva Neurosciences 386K 31K 2024-06
Nektar Therapeutics USD 4.43M 5.3M 2024-09
Neurocrine Biosciences USD 17.6M 246.4M 2025-12
Otsuka Holdings JPY 174.09B 18.65B 2026-03
Pfizer USD 6.29B 2.12B 2025-12
Regeneron Pharmaceuticals USD 669.4M 84.8M 2026-03
Vertex Pharmaceuticals USD 392.8M 73.2M 2026-03